Loading…
MAGIC versus MacDonald treatment regimens for gastric cancer: Trends and predictors of multimodal therapy for gastric cancer using the National Cancer Database
Multimodal therapy is beneficial in gastric cancer, however this practice is not universal. This study examines trends, identifies associative factors, and examines overall survival (OS) benefit from multimodal therapy in gastric cancer. Gastric cancer patients staged IB-III from 2005 to 2014, ident...
Saved in:
| Published in: | The American journal of surgery 2020-01, Vol.219 (1), p.129-135 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c393t-a2aad07d4f7a1542df85767449ce93e6b204ccdbcbc8d5162462ec8115989c63 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c393t-a2aad07d4f7a1542df85767449ce93e6b204ccdbcbc8d5162462ec8115989c63 |
| container_end_page | 135 |
| container_issue | 1 |
| container_start_page | 129 |
| container_title | The American journal of surgery |
| container_volume | 219 |
| creator | Jayanathan, Mark Erwin, Ryan P. Molacek, Nicholas Fluck, Marcus Hunsinger, Marie Wild, Jeffrey Arora, Tania K. Shabahang, Mohsen M. Franko, Jan Blansfield, Joseph A. |
| description | Multimodal therapy is beneficial in gastric cancer, however this practice is not universal. This study examines trends, identifies associative factors, and examines overall survival (OS) benefit from multimodal therapy in gastric cancer.
Gastric cancer patients staged IB-III from 2005 to 2014, identified using the National Cancer Database, were categorized by treatment: surgery alone, perioperative chemotherapy, and adjuvant chemoradiation. Groups were analyzed to identify associative factors of perioperative therapy.
We examined 9243 patients, with the majority receiving multimodal therapy (57%). The proportion of those receiving perioperative chemotherapy rose dramatically from 7.5% in 2006 to 46% in 2013. Academic center treatment was strongly associated with perioperative over adjuvant therapy (p |
| doi_str_mv | 10.1016/j.amjsurg.2019.06.005 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2251103057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002961019302636</els_id><sourcerecordid>2251103057</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-a2aad07d4f7a1542df85767449ce93e6b204ccdbcbc8d5162462ec8115989c63</originalsourceid><addsrcrecordid>eNqFkUuO1DAQhiMEYpqBI4AssWGT4EfsJGzQqIeXNAOb3lsVu9I4SuLGdkaa28xZOBludcMCIbEql-r7q8r1F8VLRitGmXo7VjCPcQ37ilPWVVRVlMpHxYa1TVeythWPiw2llJedYvSieBbjmFPGavG0uBCMK14LuSkebq8-fdmSOwxxjeQWzLVfYLIkBYQ045JIwL3Lj0gGH8geYgrOEAOLwfCO7AIuNhJYLDkEtM4kHyLxA5nXKbnZW5hI-o4BDvf_0JM1umX_8yET5CskdxxNtqfSNSToIeLz4skAU8QX53hZ7D5-2G0_lzff8uJXN6URnUglcABLG1sPDTBZczu0slFNXXcGO4Gq57Q2xvamN62VLP9ecTQtY7JrO6PEZfHm1PYQ_I8VY9KziwanCRb0a9ScS8aooLLJ6Ou_0NGvIa-eKcElV7SjR0qeKBN8jAEHfQhuhnCvGdVHB_Wozw7qo4OaKp0dzLpX5-5rP6P9o_ptWQbenwDM17hzGHQ0DvPNrAtokrbe_WfEL67Msjs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2325260907</pqid></control><display><type>article</type><title>MAGIC versus MacDonald treatment regimens for gastric cancer: Trends and predictors of multimodal therapy for gastric cancer using the National Cancer Database</title><source>ScienceDirect Journals</source><creator>Jayanathan, Mark ; Erwin, Ryan P. ; Molacek, Nicholas ; Fluck, Marcus ; Hunsinger, Marie ; Wild, Jeffrey ; Arora, Tania K. ; Shabahang, Mohsen M. ; Franko, Jan ; Blansfield, Joseph A.</creator><creatorcontrib>Jayanathan, Mark ; Erwin, Ryan P. ; Molacek, Nicholas ; Fluck, Marcus ; Hunsinger, Marie ; Wild, Jeffrey ; Arora, Tania K. ; Shabahang, Mohsen M. ; Franko, Jan ; Blansfield, Joseph A.</creatorcontrib><description>Multimodal therapy is beneficial in gastric cancer, however this practice is not universal. This study examines trends, identifies associative factors, and examines overall survival (OS) benefit from multimodal therapy in gastric cancer.
Gastric cancer patients staged IB-III from 2005 to 2014, identified using the National Cancer Database, were categorized by treatment: surgery alone, perioperative chemotherapy, and adjuvant chemoradiation. Groups were analyzed to identify associative factors of perioperative therapy.
We examined 9243 patients, with the majority receiving multimodal therapy (57%). The proportion of those receiving perioperative chemotherapy rose dramatically from 7.5% in 2006 to 46% in 2013. Academic center treatment was strongly associated with perioperative over adjuvant therapy (p < 0.0001). An OS advantage was clearly seen in those receiving multimodal therapy versus surgery alone (p < 0.0001), with no difference between perioperative and adjuvant therapies.
Treatment of gastric cancer with multimodal therapy has risen significantly since 2005, largely due to increasing use of perioperative chemotherapy. As perioperative therapy becomes more prevalent, more patients will have the opportunity for the improved survival benefit of multimodal therapy.
•Perioperative chemotherapy use increased from 7.5% to 46% in the last decade.•Overall survival was improved for multimodal therapy versus surgery alone.•Over 40% of Americans are not receiving multimodal therapy for gastric cancer.•There was no survival difference between perioperative and adjuvant therapies.</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/j.amjsurg.2019.06.005</identifier><identifier>PMID: 31262435</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adjuvant chemotherapy ; Adolescent ; Adult ; Age ; Aged ; Antineoplastic Agents - therapeutic use ; Cancer ; Cancer therapies ; Chemoradiotherapy ; Chemoradiotherapy, Adjuvant ; Chemotherapy ; Combined Modality Therapy - trends ; Databases, Factual ; Decision making ; Female ; Gastrectomy ; Gastric cancer ; Humans ; Identification methods ; Male ; Medicaid ; Medicare ; Middle Aged ; Multimodal therapy ; Neoadjuvant therapy ; Patients ; Preoperative Period ; Retrospective Studies ; Stomach Neoplasms - mortality ; Stomach Neoplasms - therapy ; Studies ; Surgeons ; Surgery ; Survival ; Survival Rate ; Trends ; Young Adult</subject><ispartof>The American journal of surgery, 2020-01, Vol.219 (1), p.129-135</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><rights>2019. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-a2aad07d4f7a1542df85767449ce93e6b204ccdbcbc8d5162462ec8115989c63</citedby><cites>FETCH-LOGICAL-c393t-a2aad07d4f7a1542df85767449ce93e6b204ccdbcbc8d5162462ec8115989c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31262435$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jayanathan, Mark</creatorcontrib><creatorcontrib>Erwin, Ryan P.</creatorcontrib><creatorcontrib>Molacek, Nicholas</creatorcontrib><creatorcontrib>Fluck, Marcus</creatorcontrib><creatorcontrib>Hunsinger, Marie</creatorcontrib><creatorcontrib>Wild, Jeffrey</creatorcontrib><creatorcontrib>Arora, Tania K.</creatorcontrib><creatorcontrib>Shabahang, Mohsen M.</creatorcontrib><creatorcontrib>Franko, Jan</creatorcontrib><creatorcontrib>Blansfield, Joseph A.</creatorcontrib><title>MAGIC versus MacDonald treatment regimens for gastric cancer: Trends and predictors of multimodal therapy for gastric cancer using the National Cancer Database</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>Multimodal therapy is beneficial in gastric cancer, however this practice is not universal. This study examines trends, identifies associative factors, and examines overall survival (OS) benefit from multimodal therapy in gastric cancer.
Gastric cancer patients staged IB-III from 2005 to 2014, identified using the National Cancer Database, were categorized by treatment: surgery alone, perioperative chemotherapy, and adjuvant chemoradiation. Groups were analyzed to identify associative factors of perioperative therapy.
We examined 9243 patients, with the majority receiving multimodal therapy (57%). The proportion of those receiving perioperative chemotherapy rose dramatically from 7.5% in 2006 to 46% in 2013. Academic center treatment was strongly associated with perioperative over adjuvant therapy (p < 0.0001). An OS advantage was clearly seen in those receiving multimodal therapy versus surgery alone (p < 0.0001), with no difference between perioperative and adjuvant therapies.
Treatment of gastric cancer with multimodal therapy has risen significantly since 2005, largely due to increasing use of perioperative chemotherapy. As perioperative therapy becomes more prevalent, more patients will have the opportunity for the improved survival benefit of multimodal therapy.
•Perioperative chemotherapy use increased from 7.5% to 46% in the last decade.•Overall survival was improved for multimodal therapy versus surgery alone.•Over 40% of Americans are not receiving multimodal therapy for gastric cancer.•There was no survival difference between perioperative and adjuvant therapies.</description><subject>Adjuvant chemotherapy</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemoradiotherapy</subject><subject>Chemoradiotherapy, Adjuvant</subject><subject>Chemotherapy</subject><subject>Combined Modality Therapy - trends</subject><subject>Databases, Factual</subject><subject>Decision making</subject><subject>Female</subject><subject>Gastrectomy</subject><subject>Gastric cancer</subject><subject>Humans</subject><subject>Identification methods</subject><subject>Male</subject><subject>Medicaid</subject><subject>Medicare</subject><subject>Middle Aged</subject><subject>Multimodal therapy</subject><subject>Neoadjuvant therapy</subject><subject>Patients</subject><subject>Preoperative Period</subject><subject>Retrospective Studies</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - therapy</subject><subject>Studies</subject><subject>Surgeons</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Trends</subject><subject>Young Adult</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkUuO1DAQhiMEYpqBI4AssWGT4EfsJGzQqIeXNAOb3lsVu9I4SuLGdkaa28xZOBludcMCIbEql-r7q8r1F8VLRitGmXo7VjCPcQ37ilPWVVRVlMpHxYa1TVeythWPiw2llJedYvSieBbjmFPGavG0uBCMK14LuSkebq8-fdmSOwxxjeQWzLVfYLIkBYQ045JIwL3Lj0gGH8geYgrOEAOLwfCO7AIuNhJYLDkEtM4kHyLxA5nXKbnZW5hI-o4BDvf_0JM1umX_8yET5CskdxxNtqfSNSToIeLz4skAU8QX53hZ7D5-2G0_lzff8uJXN6URnUglcABLG1sPDTBZczu0slFNXXcGO4Gq57Q2xvamN62VLP9ecTQtY7JrO6PEZfHm1PYQ_I8VY9KziwanCRb0a9ScS8aooLLJ6Ou_0NGvIa-eKcElV7SjR0qeKBN8jAEHfQhuhnCvGdVHB_Wozw7qo4OaKp0dzLpX5-5rP6P9o_ptWQbenwDM17hzGHQ0DvPNrAtokrbe_WfEL67Msjs</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Jayanathan, Mark</creator><creator>Erwin, Ryan P.</creator><creator>Molacek, Nicholas</creator><creator>Fluck, Marcus</creator><creator>Hunsinger, Marie</creator><creator>Wild, Jeffrey</creator><creator>Arora, Tania K.</creator><creator>Shabahang, Mohsen M.</creator><creator>Franko, Jan</creator><creator>Blansfield, Joseph A.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>202001</creationdate><title>MAGIC versus MacDonald treatment regimens for gastric cancer: Trends and predictors of multimodal therapy for gastric cancer using the National Cancer Database</title><author>Jayanathan, Mark ; Erwin, Ryan P. ; Molacek, Nicholas ; Fluck, Marcus ; Hunsinger, Marie ; Wild, Jeffrey ; Arora, Tania K. ; Shabahang, Mohsen M. ; Franko, Jan ; Blansfield, Joseph A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-a2aad07d4f7a1542df85767449ce93e6b204ccdbcbc8d5162462ec8115989c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adjuvant chemotherapy</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemoradiotherapy</topic><topic>Chemoradiotherapy, Adjuvant</topic><topic>Chemotherapy</topic><topic>Combined Modality Therapy - trends</topic><topic>Databases, Factual</topic><topic>Decision making</topic><topic>Female</topic><topic>Gastrectomy</topic><topic>Gastric cancer</topic><topic>Humans</topic><topic>Identification methods</topic><topic>Male</topic><topic>Medicaid</topic><topic>Medicare</topic><topic>Middle Aged</topic><topic>Multimodal therapy</topic><topic>Neoadjuvant therapy</topic><topic>Patients</topic><topic>Preoperative Period</topic><topic>Retrospective Studies</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - therapy</topic><topic>Studies</topic><topic>Surgeons</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Trends</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jayanathan, Mark</creatorcontrib><creatorcontrib>Erwin, Ryan P.</creatorcontrib><creatorcontrib>Molacek, Nicholas</creatorcontrib><creatorcontrib>Fluck, Marcus</creatorcontrib><creatorcontrib>Hunsinger, Marie</creatorcontrib><creatorcontrib>Wild, Jeffrey</creatorcontrib><creatorcontrib>Arora, Tania K.</creatorcontrib><creatorcontrib>Shabahang, Mohsen M.</creatorcontrib><creatorcontrib>Franko, Jan</creatorcontrib><creatorcontrib>Blansfield, Joseph A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jayanathan, Mark</au><au>Erwin, Ryan P.</au><au>Molacek, Nicholas</au><au>Fluck, Marcus</au><au>Hunsinger, Marie</au><au>Wild, Jeffrey</au><au>Arora, Tania K.</au><au>Shabahang, Mohsen M.</au><au>Franko, Jan</au><au>Blansfield, Joseph A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MAGIC versus MacDonald treatment regimens for gastric cancer: Trends and predictors of multimodal therapy for gastric cancer using the National Cancer Database</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>2020-01</date><risdate>2020</risdate><volume>219</volume><issue>1</issue><spage>129</spage><epage>135</epage><pages>129-135</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><abstract>Multimodal therapy is beneficial in gastric cancer, however this practice is not universal. This study examines trends, identifies associative factors, and examines overall survival (OS) benefit from multimodal therapy in gastric cancer.
Gastric cancer patients staged IB-III from 2005 to 2014, identified using the National Cancer Database, were categorized by treatment: surgery alone, perioperative chemotherapy, and adjuvant chemoradiation. Groups were analyzed to identify associative factors of perioperative therapy.
We examined 9243 patients, with the majority receiving multimodal therapy (57%). The proportion of those receiving perioperative chemotherapy rose dramatically from 7.5% in 2006 to 46% in 2013. Academic center treatment was strongly associated with perioperative over adjuvant therapy (p < 0.0001). An OS advantage was clearly seen in those receiving multimodal therapy versus surgery alone (p < 0.0001), with no difference between perioperative and adjuvant therapies.
Treatment of gastric cancer with multimodal therapy has risen significantly since 2005, largely due to increasing use of perioperative chemotherapy. As perioperative therapy becomes more prevalent, more patients will have the opportunity for the improved survival benefit of multimodal therapy.
•Perioperative chemotherapy use increased from 7.5% to 46% in the last decade.•Overall survival was improved for multimodal therapy versus surgery alone.•Over 40% of Americans are not receiving multimodal therapy for gastric cancer.•There was no survival difference between perioperative and adjuvant therapies.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31262435</pmid><doi>10.1016/j.amjsurg.2019.06.005</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9610 |
| ispartof | The American journal of surgery, 2020-01, Vol.219 (1), p.129-135 |
| issn | 0002-9610 1879-1883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2251103057 |
| source | ScienceDirect Journals |
| subjects | Adjuvant chemotherapy Adolescent Adult Age Aged Antineoplastic Agents - therapeutic use Cancer Cancer therapies Chemoradiotherapy Chemoradiotherapy, Adjuvant Chemotherapy Combined Modality Therapy - trends Databases, Factual Decision making Female Gastrectomy Gastric cancer Humans Identification methods Male Medicaid Medicare Middle Aged Multimodal therapy Neoadjuvant therapy Patients Preoperative Period Retrospective Studies Stomach Neoplasms - mortality Stomach Neoplasms - therapy Studies Surgeons Surgery Survival Survival Rate Trends Young Adult |
| title | MAGIC versus MacDonald treatment regimens for gastric cancer: Trends and predictors of multimodal therapy for gastric cancer using the National Cancer Database |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T06%3A35%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MAGIC%20versus%20MacDonald%20treatment%20regimens%20for%20gastric%20cancer:%20Trends%20and%20predictors%20of%20multimodal%20therapy%20for%20gastric%20cancer%20using%C2%A0the%20National%20Cancer%20Database&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=Jayanathan,%20Mark&rft.date=2020-01&rft.volume=219&rft.issue=1&rft.spage=129&rft.epage=135&rft.pages=129-135&rft.issn=0002-9610&rft.eissn=1879-1883&rft_id=info:doi/10.1016/j.amjsurg.2019.06.005&rft_dat=%3Cproquest_cross%3E2251103057%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c393t-a2aad07d4f7a1542df85767449ce93e6b204ccdbcbc8d5162462ec8115989c63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2325260907&rft_id=info:pmid/31262435&rfr_iscdi=true |